Literature DB >> 18212095

In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.

Maria-Teresa Illnait-Zaragozi1, Gerardo F Martínez, Ilse Curfs-Breuker, Carlos M Fernández, Teun Boekhout, Jacques F Meis.   

Abstract

Cuban Cryptococcus isolates (n = 165) were tested in vitro against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole, giving MIC90 values of 0.25, 8, 4, 0.25, 0.125, 0.016, and 0.016 microg/ml, respectively. Isavuconazole and posaconazole seem to be potentially active drugs for treating cryptococcal infections.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18212095      PMCID： PMC2292518          DOI： 10.1128/AAC.01384-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.

Authors:  Hassan A Abdel-Salam
Journal:  Mycoses       Date:  2005-09       Impact factor: 4.377

Review 2.  Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal.

Authors:  Frank C Odds
Journal:  Curr Opin Investig Drugs       Date:  2006-08

3.  Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.

Authors:  Patrick Schwarz; Guilhem Janbon; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

4.  In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Authors:  F Sabatelli; R Patel; P A Mann; C A Mendrick; C C Norris; R Hare; D Loebenberg; T A Black; P M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.

Authors:  A J Ullmann; O A Cornely; A Burchardt; R Hachem; D P Kontoyiannis; K Töpelt; R Courtney; D Wexler; G Krishna; M Martinho; G Corcoran; I Raad
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

6.  Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.

Authors:  E Dannaoui; M Abdul; M Arpin; A Michel-Nguyen; M A Piens; A Favel; O Lortholary; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 7.  Management of systemic fungal infections: alternatives to itraconazole.

Authors:  R Herbrecht; Y Nivoix; C Fohrer; S Natarajan-Amé; V Letscher-Bru
Journal:  J Antimicrob Chemother       Date:  2005-09       Impact factor: 5.790

Review 8.  Posaconazole: a broad-spectrum triazole antifungal.

Authors:  Harrys A Torres; Ray Y Hachem; Roy F Chemaly; Dimitrios P Kontoyiannis; Issam I Raad
Journal:  Lancet Infect Dis       Date:  2005-12       Impact factor: 25.071

9.  Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Markus Heep; Michael Schleimer; Erhard Weidekamm; Tom Brown; Michael Roehrle; Christoph Beglinger
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938

10.  Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Jürgen Maares; Markus Heep; Jochen Spickerman; Erhard Weidekamm; Tom Brown; Michael Roehrle
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938
View more
  24 in total

Review 1.  Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.

Authors:  George R Thompson; Nathan P Wiederhold
Journal:  Mycopathologia       Date:  2010-06-05       Impact factor: 2.574

2.  Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.

Authors:  Mariana Castanheira; Shawn A Messer; Paul R Rhomberg; Rachel R Dietrich; Ronald N Jones; Michael A Pfaller
Journal:  Mycopathologia       Date:  2014-06-21       Impact factor: 2.574

3.  A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.

Authors:  J Viljoen; N Azie; A-H Schmitt-Hoffmann; M Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2015-01-05       Impact factor: 5.191

4.  Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population.

Authors:  Ferry Hagen; María-Teresa Illnait-Zaragozí; Jacques F Meis; William H M Chew; Ilse Curfs-Breuker; Johan W Mouton; Andy I M Hoepelman; Lodewijk Spanjaard; Paul E Verweij; Greetje A Kampinga; Ed J Kuijper; Teun Boekhout; Corné H W Klaassen
Journal:  J Clin Microbiol       Date:  2012-03-21       Impact factor: 5.948

5.  Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Jacques F Meis; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

6.  Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.

Authors:  P F Herkert; F Hagen; G L de Oliveira Salvador; R R Gomes; M S Ferreira; V A Vicente; M D Muro; R L Pinheiro; J F Meis; F Queiroz-Telles
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-01       Impact factor: 3.267

7.  Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.

Authors:  A Espinel-Ingroff; A Chowdhary; M Cuenca-Estrella; A Fothergill; J Fuller; F Hagen; N Govender; J Guarro; E Johnson; C Lass-Flörl; S R Lockhart; M A Martins; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M A Pfaller; W A Schell; L Trilles; S Kidd; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

8.  Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.

Authors:  A Schmitt-Hoffmann; B Roos; J Spickermann; M Heep; E Peterfaí; D J Edwards; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  2009-08-10       Impact factor: 5.191

9.  Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug.

Authors:  Shawn R Lockhart; Elizabeth L Berkow
Journal:  Clin Microbiol Newsl       Date:  2016-07

10.  In vitro antifungal activity of isavuconazole against Madurella mycetomatis.

Authors:  Wendy Kloezen; Jacques F Meis; Ilse Curfs-Breuker; Ahmed H Fahal; Wendy W J van de Sande
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.